The battle for GLP-1 generics begins! Indian pharmaceutical companies start by slashing prices by an order of magnitude.

Ask AI · Why can India’s generic drug price war get so fierce?

Caixin Global, March 20 (Editor Shi Zhengcheng) With the patent protection for Novo Nordisk’s bestselling weight-loss drug expiring in India— the world’s No. 1 country for generic drugs—early Saturday morning, a “GLP-1 generic drug battle” is already poised.

Not long before publication, Natco Pharma, an Indian listed company (NATCO Pharma), issued an announcement stating that it will launch a generic version on the first day the semaglutide patent expires (March 21), with the multi-dose vial version starting at 1,290 Indian rupees per month (about $13.8 / RMB 95 yuan). The company will also roll out the injection pen version in April, starting at 4,000 Indian rupees (about $42).

(Source: Company website)

For comparison, Novo Nordisk’s Wegovy (the domestic brand name is Novo Yin) injection pen in India starts at about 10,480 rupees (about $112).

According to records from Indian listed companies and earnings call transcripts, including at least 12 major Indian pharmaceutical companies such as Sun Pharma and Dr. Reddy’s Laboratories have already clearly stated that they will launch generic semaglutide in the near term, but the actual competitive scale will be much larger.

Statistics from market data company Pharmarack show that this year in the Indian market, 42 pharmaceutical companies—including some smaller manufacturers—will launch the same type of generic drug under 50 brand names.

According to insiders, other Indian drug manufacturers may set the initial dose price at between 3,000 and 5,000 rupees per month.

In addition to “scrapping prices,” Indian drugmakers are also testing various routes of administration, including single-use injection pens, medicine vials, and reusable injection pens with adjustable dosages.

Pharmarack researcher Sheetal Sapale said that because the foundation of these generics is all semaglutide, the company’s reputation and its delivery system will become decisive factors. Once consumers get used to a particular delivery device, they usually don’t switch.

From a global market perspective, within 2026, Novo Nordisk will face competition from semaglutide generics in regions accounting for 40% of the world’s population. Besides India, patent protection for semaglutide in the Chinese market will also expire today. Patent protection for this drug in Brazil, Türkiye, and South Africa will also expire within the year.

Previously, the patent for this molecule in Canada had already expired in January due to “failure to pay maintenance fees,” but Canada’s drug regulator has not approved any generics to date. This makes India the first market to see a large wave of GLP-1 generics. Many Indian drugmakers also view selling GLP-1 generics to Canada as an important business goal.

Last July, Erez Israeli, CEO of Dr. Reddy’s Laboratories, said that the company has already turned its attention to 87 global markets for selling GLP-1 generics.

The analysis points out that once GLP-1 weight-loss drugs are listed in Canada, many U.S. consumers may choose to cross the border to buy cheaper generics from Canadian pharmacies. Also, Florida—a U.S. state that allows imports of Canadian drugs—may cause “leakage” of generics into the U.S. domestic market. At present, the out-of-pocket starting price of this drug in the U.S. is 199 dollars per month.

India’s unique profile in the generics space also makes it an important case study for economic observation. In a recent research report, the team of analysts at Jefferies wrote that India’s weight-loss drug market is about $500 million, but “with the right pricing, adoption rates, and government incentives, it could grow to $1 billion.”

(Caixin Global, Shi Zhengcheng)